Date: 2015-04-13
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia
Company: Iomet Pharma (UK)
Product: IDO1, TDO and IDO1/TDO Dual Inhibitor programs
Action
mechanism: IDO1/TDO inhibitor. IDO1 (indoleamine-2,3-dioxygenase 1) and TDO (tryptophan-2,3-dioxygenase) are rate-limiting enzymes in the pathway that metabolises the essential amino acid tryptophan. Overexpression of these enzymes has been detected in a variety of cancers, including glioma, melanoma, lung, ovarian and colorectal cancers, and is associated with poor prognosis and survival. IDO1 and TDO overexpression leads to tryptophan depletion and high tumour levels of the breakdown product, kynurenine. This elevated kynurenine/tryptophan (K/T) ratio supresses the body’s immune response to cancer, thus facilitating tumour progression and metastasis. Extensive preclinical evidence, and emerging clinical data, suggests that inhibition of IDO1 and/or TDO may synergise with, and help overcome resistance to, existing clinical cancer therapies, in particular other immunotherapy-based treatments. IOmet is developing multiple, distinct novel chemical series of potent, IDO1-selective, TDO-selective and dual-acting IDO1/TDO inhibitors. have emerged as key targets for the pharmaceutical industry in the cancer immunotherapy field.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 13, 2015, IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, announced the presentation of data demonstrating superior properties of its novel, pre-clinical IDO1, TDO and IDO1/TDO Dual Inhibitor programs at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia on April 22.
